References
- Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 1, 1335–1342, 2017.
- Do C, Vasquez PC, Soleimani M. Metabolic alkalosis pathogenesis, diagnosis, and treatment: Core curriculum 2022. Am J Kidney Dis 80, 536–551, 2022.
- Gadelha M, Gatto F, Wildemberg LE, Fleseriu M. Cushing’s syndrome. Lancet 402, 2237–2252, 2023.
- Kamp K, Alwani RA, Korpershoek E, Franssen GJ, de Herder WW, Feelders RA. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. Eur J Endocrinol 174, 271–280, 2016.
- Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33, 115–154, 2022.
- Rizen EN, Phan AT. Neuroendocrine tumors: a relevant clinical update. Curr Oncol Rep 24, 703–714, 2022.
- White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, George G, Russell B, Srirajaskanthan R, Ramage JK. Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study. Lancet Reg Health Eur 23, 100510, 2022.
- Yan L, Xu Y, Pan J, Bai J, Long Q, He N, Hu P, Liu M, Ji H, Li X, Tang Q. Prognostic evaluation of patients with rectal neuroendocrine neoplasms and hepatic metastases: A SEER database Analysis. J Oncol 2022, 2451282, 2022.